Zhang X Y, Zhou D F, Su J M, Zhang P Y
Department of Biochemistry, Institute of Mental Health, Beijing Medical University, People's Republic of China.
J Clin Psychopharmacol. 2001 Feb;21(1):85-8. doi: 10.1097/00004714-200102000-00015.
The purpose of the study was to evaluate the effect of the classic antipsychotic haloperidol plus extract of ginkgo biloba (EGb) on treatment-resistant chronic schizophrenia and on blood superoxide dismutase (SOD) levels. Eighty-two patients with chronic refractory schizophrenia were studied. Forty-three patients were treated with haloperidol plus extract of ginkgo biloba (group 1), and 39 received haloperidol plus placebo (group 2). SOD levels of these patients were measured before and after treatment and were compared with SOD levels of 30 healthy volunteers. Therapeutic efficiency was equated with a change in clinical rating scores assessed by standardized measurement tools that included the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms (SANS) over this period. Patients in group 1 improved significantly as demonstrated by scores from these two assessment instruments; those in group 2 improved significantly only as shown by scores on SANS. SOD levels before treatment in all patients were significantly higher than those in healthy controls; after treatment, the SOD level decreased significantly in group 1 but not in group 2. These results suggest that EGb may enhance the efficiency of the classic antipsychotic haloperidol in patients with schizophrenia, especially on their positive symptoms, and that EGb may work through an antioxidant effect that is involved in the therapeutic mechanism in patients with chronic refractory schizophrenia.
该研究的目的是评估经典抗精神病药物氟哌啶醇加银杏叶提取物（EGb）对难治性慢性精神分裂症的疗效以及对血液中超氧化物歧化酶（SOD）水平的影响。对82例慢性难治性精神分裂症患者进行了研究。43例患者接受氟哌啶醇加银杏叶提取物治疗（第1组），39例接受氟哌啶醇加安慰剂治疗（第2组）。在治疗前后测量这些患者的SOD水平，并与30名健康志愿者的SOD水平进行比较。治疗效果通过标准化测量工具评估的临床评分变化来衡量，这些工具包括阳性症状评定量表和阴性症状评定量表（SANS）。第1组患者在这两种评估工具的评分中均有显著改善；第2组患者仅在SANS评分中显示出显著改善。所有患者治疗前的SOD水平显著高于健康对照组；治疗后，第1组的SOD水平显著下降，而第2组则没有。这些结果表明，EGb可能提高经典抗精神病药物氟哌啶醇对精神分裂症患者的疗效，尤其是对其阳性症状的疗效，并且EGb可能通过抗氧化作用发挥作用，这一作用参与了慢性难治性精神分裂症患者的治疗机制。
